Welcome to our dedicated page for LB Pharmaceuticals SEC filings (Ticker: LBRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
LB Pharmaceuticals Inc filings document a Nasdaq-listed Delaware biopharmaceutical company developing LB-102 for neuropsychiatric diseases. Registration statements describe securities offerings and capital-structure terms for common stock, while current reports record operating and financial results, clinical-development updates, material agreements and governance events.
Proxy materials cover annual meeting matters, director elections and auditor ratification. The filing record also includes disclosures on executive and board changes, compensatory arrangements, inducement equity awards, lease agreements and shareholder voting matters tied to a late-stage drug development company.
LB Pharmaceuticals Inc. is asking stockholders to vote at its virtual 2026 annual meeting on June 3, 2026. Investors will elect three Class I directors and ratify the appointment of BDO USA, P.C. as independent auditor for the year ending December 31, 2026.
The company has a classified nine‑member board and states that a majority of directors are independent under Nasdaq rules, with Scott Garland serving as independent chair. Committees oversee audit, compensation, and governance, and the proxy details director qualifications, independence determinations, and risk‑oversight responsibilities.
The filing outlines executive pay, including 2025 total compensation of $11,884,985 for CEO Heather Turner, largely driven by stock options, and explains annual bonus targets of 55% of salary for the CEO and 40% for key officers. It also discloses severance and change‑in‑control protections, and shows BDO audit fees of $616,325 in 2025 and total fees of $658,325.
LB Pharmaceuticals Inc registered for resale up to 4,778,491 shares of Common Stock pursuant to a prospectus dated April 14, 2026, covering (i) 4,723,678 shares related to a February 4, 2026 PIPE (including 3,306,571 outstanding shares and 1,417,107 issuable upon exercise of pre-funded warrants) and (ii) 54,813 shares issued to Maxim upon exercise of prior warrants. The registration permits resale "from time to time" by the Selling Stockholders; the company will not receive proceeds from these resales except for the $0.0001 per-share exercise price of any pre-funded warrants exercised for cash. The prospectus states resale methods may include fixed price, market-price, negotiated transactions, underwriters, broker-dealers or agents. The company reported a Nasdaq last sale price of $25.69 per share as of April 2, 2026.
LB Pharmaceuticals Inc is registering up to 4,778,491 shares of common stock for resale by existing holders. The registration covers 4,723,678 shares held by PIPE investors, including 3,306,571 outstanding shares and 1,417,107 shares issuable upon exercise of pre-funded warrants, plus 54,813 shares issued to Maxim Partners LLC.
The company will not receive proceeds from the resale of these shares, other than the nominal $0.0001 per share exercise price if any pre-funded warrants are exercised for cash. LB Pharmaceuticals is a late-stage biopharmaceutical company focused on LB-102, a lead candidate for schizophrenia, bipolar depression, and adjunctive major depressive disorder.
LB Pharmaceuticals Inc. is a late-stage biopharmaceutical company focused on neuropsychiatric disorders, built around its lead candidate LB-102, a novel, methylated benzamide antipsychotic. LB-102 is designed to improve on amisulpride by enhancing blood–brain barrier penetration, enabling lower, once-daily dosing while preserving a selective D2/D3/5-HT7 receptor profile.
The company reported positive results from a four-week Phase 2 trial in acute schizophrenia, where LB-102 achieved statistically significant reductions in PANSS total scores across 50 mg, 75 mg, and 100 mg doses, with responder rates up to 78.3% and a tolerability profile characterized by low rates of EPS (including akathisia), minimal sedation, and few gastrointestinal effects. Exploratory analyses suggested benefits on negative symptoms and cognition using the CogState battery, with effect sizes increasing by dose and mediation analyses indicating a primarily direct cognitive effect.
LB Pharmaceuticals has initiated a six-week Phase 3 schizophrenia trial (NOVA-2) in the United States comparing 50 mg and 100 mg LB-102 versus placebo, targeting approximately 460 patients, and expects topline data in the second half of 2027. It is also running or planning Phase 2 programs in bipolar 1 depression (ILLUMINATE-1, topline data expected in the first quarter of 2028) and adjunctive major depressive disorder, and is developing a long-acting injectable formulation to address adherence. The company holds global rights to LB-102 and intends to retain U.S. commercialization while evaluating ex-U.S. collaborations.
LB Pharmaceuticals reported another net loss for 2025 but with a much stronger balance sheet and advancing clinical pipeline. Net loss for 2025 was about $25.2 million, a sharp improvement from $63.1 million in 2024, as operating loss narrowed and non-operating income increased.
Cash, cash equivalents and investments were $295.2 million as of December 31, 2025, compared with $28.0 million a year earlier, supported by an IPO and a recent $100 million private placement. The company expects this to fund operations into the second quarter of 2029.
Operationally, LB reported positive Phase 2 results for LB-102 in acute schizophrenia and has started the pivotal Phase 3 NOVA-2 trial in schizophrenia and the Phase 2 ILLUMINATE-1 trial in bipolar depression, with a Phase 2 adjunctive MDD study planned for early 2027.
LB Pharmaceuticals Inc reported that director Zachary Prensky plans to retire from the Board and will not stand for reelection at the company’s 2026 annual meeting of stockholders. His current term will end at the conclusion of that meeting, and he will continue serving on the Board and the Nominating and Corporate Governance Committee until then.
The company stated that Mr. Prensky’s decision was not due to any disagreement regarding operations, policies, or practices. After his Board service ends, he is expected to provide consulting services under an amended Transition, Separation, and Consulting Agreement, which allows his unvested stock options to continue vesting during the agreement term.
LB Pharmaceuticals director Robert A. Lenz received a grant of stock options for 20,000 shares of common stock. The options have an exercise price of $23.78 per share and expire on March 5, 2036. They vest in three equal annual installments on March 6, 2027, March 6, 2028, and March 6, 2029, contingent on continued service. Following this grant, he holds 20,000 derivative securities directly.
LB PHARMACEUTICALS INC director Robert A. Lenz filed an initial ownership report on Form 3. This filing establishes his status as a director and formally records his position as an insider of the company, but it does not list any specific share transactions or derivative holdings.
LB Pharmaceuticals Inc appointed Robert A. Lenz, M.D., Ph.D., to its Board of Directors as a Class I director, with a term running through the 2026 annual stockholder meeting, and named him to the Nominating and Corporate Governance Committee.
Under the non-employee director compensation policy, Dr. Lenz will receive a $40,000 annual board retainer, a $5,000 annual committee retainer, an initial option to purchase 20,000 shares vesting over three years, and annual options for 10,000 shares vesting by the next annual meeting.
The Board also promoted Gad Soffer to Chief Operating and Business Officer, with at-will employment, an annual base salary of $505,000, and eligibility for an annual bonus targeted at 40% of base salary. The company describes itself as a late-stage biopharmaceutical firm advancing lead candidate LB-102 for multiple neuropsychiatric indications.